Anti-vascular endothelial growth factor therapy for diabetic macular edema - Wikidata - thesis-toulmin - TriplyDB

Anti-vascular endothelial growth factor therapy for diabetic macular edema

Anti-vascular endothelial growth factor therapy for diabetic macular edema

http://www.wikidata.org/entity/Q35064343

about

Anatomical effects of dexamethasone intravitreal implant in diabetic macular oedema: a pooled analysis of 3-year phase III trials Diabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomics Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases Immune and inflammatory processes in obesity, insulin resistance, diabetes, and related cardiometabolic complications Advances in diabetic retinopathy.Angiogenic potential of vitreous from Proliferative Diabetic Retinopathy and Eales' Disease patients.Modulation of VEGF-induced retinal vascular permeability by peroxisome proliferator-activated receptor-β/δ.Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant.Novel Therapies in Development for Diabetic Macular Edema.Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study.Combined Use of Oligopeptides, Fragment Libraries, and Natural Compounds: A Comprehensive Approach To Sample the Druggability of Vascular Endothelial Growth Factor.Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN(®)) in Patients with Diabetic Macular Edema Electronic Patient Records to Identify Patients in the United Kingdom with Diabetic Macular Oedema Suitable for ILUVIEN(®) (Fluocinolone Acetonide).Sub-threshold micro-pulse diode laser treatment in diabetic macular edema: A Meta-analysis of randomized controlled trials.Evidence-Based Treatment of Diabetic Macular Edema.Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1).Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.Dual Anti-Inflammatory and Anti-Angiogenic Action of miR-15a in Diabetic Retinopathy.Dietary Compound Chrysin Inhibits Retinal Neovascularization with Abnormal Capillaries in db/db Mice.Real-Life ILUVIEN (Fluocinolone Acetonide) Case Study: Rapid Drying of the Macula and Improved Vision within 2 Years after Therapy Initiation.Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies.Diabetic Retinopathy and Diabetic Macular Edema.The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy.Lipid-based drug delivery systems in the treatment of wet age-related macular degeneration.Ten Emerging Trends in the Epidemiology of Diabetic Retinopathy.Diabetes enhances the efficacy of AAV2 vectors in the retina: therapeutic effect of AAV2 encoding vasoinhibin and soluble VEGF receptor 1.Cellular Reparative Mechanisms of Mesenchymal Stem Cells for Retinal Diseases.Emodin-loaded magnesium silicate hollow nanocarriers for anti-angiogenesis treatment through inhibiting VEGF.Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials.Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies.The Role of Microglia in Diabetic Retinopathy: Inflammation, Microvasculature Defects and Neurodegeneration.Engineering functional inorganic-organic hybrid systems: advances in siRNA therapeutics.Intraocular Penetration of a vNAR: In Vivo and In Vitro VEGF165 Neutralization.Angiogenesis and Inflammation Crosstalk in Diabetic Retinopathy.Basis and Design of a Randomized Clinical Trial to Evaluate the Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema.Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies.Chrysin Ameliorates Malfunction of Retinoid Visual Cycle through Blocking Activation of AGE-RAGE-ER Stress in Glucose-Stimulated Retinal Pigment Epithelial Cells and Diabetic Eyes

P2860

Q24658545-98B31B7F-6E64-4E4E-A108-C4026311C6EC Q26998543-B5CCE92D-0304-4278-A011-E7D16BB1E14C Q33705724-F9FEC444-3AA8-450F-B2A5-13CC22B55A47 Q33840787-181EC682-49A7-4004-8E31-A339C42B6339 Q34307131-EBA3D062-6156-434F-8DAD-79C997AD27C0 Q34319662-A9F58049-0C6B-494F-BEFF-8322D7A43CA9 Q34331514-0A6E494B-14F7-49B0-9ED3-304559A0E431 Q34741796-332F5FD6-AC8E-4E96-BFAA-B29E30BEBD48 Q35128723-1890E379-CE49-4535-94DC-EC889114867E Q35751912-860851EE-16CA-48C8-A650-D9A8DEF9BEE3 Q35828114-4A4A5BDD-CA1C-4DE4-8A55-08AA2FE9FF93 Q35836815-C066CB19-BD1E-40DA-88F4-953BB4C625E9 Q35870506-B3AEC4E3-027D-4805-BFE4-3AD4EDA1311F Q35884438-C9AD93AF-1358-4E69-A241-50F694DCAFBE Q35925938-DCC37916-A9BB-4F2E-AA29-F05181E1BB9E Q36021525-E3E89A0D-DEC1-42FA-85F3-476324968F29 Q36097239-0E03E366-402D-49A1-B8B4-B291F46D06A2 Q36242390-EEFE567F-19FA-4A2A-8190-6E04A6D2B2BC Q36297613-3462E560-ADEE-4365-8106-22508E4B766A Q36762577-8C5C1EA1-DFE2-4A3D-A136-6B23C1664930 Q37309486-BF32C5FF-AC35-4782-9166-85D3E70F9A72 Q37535413-AD464EE7-BBCE-429A-82CB-76FB2AA5FA6D Q37603037-BBF8883A-736D-4B75-A636-BC08E889609D Q38229636-659454A9-1084-4216-BB33-12576A6FA72D Q38616344-424F765B-60BE-42B2-B38C-C1ABD63AD5FD Q38710512-58C397A5-CB58-4DA7-9682-223CE210B6F3 Q38837906-6F48E888-F7DC-47DD-9561-1CBBD78A31A1 Q38880569-DAA680A9-8D2A-4BCC-9D83-CF2B38EBBBE6 Q41122957-0DBCF4EC-5D49-4093-8170-4E415EF1D03D Q41572871-74372BC5-466D-4AE0-9088-7B3532E16780 Q42002414-15EF2080-DF86-4208-86C8-19C94422CC14 Q42602540-38CC9A1D-22DC-47C7-8241-15A752AE07E1 Q47428173-CF811B9E-CA16-4537-B650-C4C7474719CB Q48308877-E0A1EB85-C8DE-4908-AB0C-CA97972773EF Q50123721-E159448E-84B3-4982-8E03-B50C6315F773 Q52609710-F144D38F-032F-42A4-8B80-AC8590BD53EE Q53111788-09CF932E-7CA8-41CC-981E-7178E7911FBD Q54988945-C288AE7A-F5B6-459B-B980-E2535FDE3155 Q55201911-7171B6D2-6231-4BA1-96C1-5E4EC802C0FB Q58795147-9C597D8F-F31C-454F-8DA3-D10181528C30

P2860

Anti-vascular endothelial growth factor therapy for diabetic macular edema

http://www.wikidata.org/entity/Q35064343

description

2013 nî lūn-bûn

@nan

2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Anti-vascular endothelial growth factor therapy for diabetic macular edema

@ast

Anti-vascular endothelial growth factor therapy for diabetic macular edema

@en

type

label

Anti-vascular endothelial growth factor therapy for diabetic macular edema

@ast

Anti-vascular endothelial growth factor therapy for diabetic macular edema

@en

prefLabel

Anti-vascular endothelial growth factor therapy for diabetic macular edema

@ast

Anti-vascular endothelial growth factor therapy for diabetic macular edema

@en

P1433

Q35064343-6D493140-5334-4135-BACB-328A0D50994B

P1476

Q35064343-9A9D2363-004B-4622-8337-4235CB2826BC

P2093

Q35064343-0692B41C-2E44-43A1-8B3B-3043F7A461E5

Q35064343-14F0EDFF-85B3-489B-A355-2EB02C9CF7C9

Q35064343-49AB05EB-E4C9-4E8C-A5B7-5EB303682A2D

Q35064343-D5C7ABAD-CCAE-4E52-96C3-0FD5002DC422

P2860

Q35064343-036FCD30-7437-486B-BD84-E900468B6415

Q35064343-06345DC2-EC7C-40BE-8607-65D9A06CC3CF

Q35064343-06AF4288-86E1-4E9D-94CB-72CC57B65D24

Q35064343-08DF430F-9839-443A-B257-2DB9A8A3658D

Q35064343-104B1219-D6CF-4575-9631-6C7542A7D502

Q35064343-16AE9747-C784-49B8-8DD7-7C596D1A42CD

Q35064343-1C7687F4-190A-404B-AF8F-A9C86CC841FE

Q35064343-22EA569F-E9AA-41FB-B080-EFF6BF3C173C

Q35064343-257CC909-85F5-43D2-AE0D-0EC8ADC4C0D9

Q35064343-2CDAD631-3DBC-4236-9B78-9BA1612E02A0

P304

Q35064343-95923833-1FFF-4D92-A108-C175E66165BE

P31

Q35064343-F5FC1111-8076-4BB5-8240-FE4F09F3A05D

P356

Q35064343-D6578514-6F65-4226-A778-F9831142916E

P433

Q35064343-90A00DB0-57DF-4571-A2C8-18BAB87401C0

P478

Q35064343-45D6332C-CDAB-4D9F-A06B-EEF46A3DD490

P577

Q35064343-F66BDFD7-8E6E-44C8-A268-6EFEA0639BA4

P698

Q35064343-9B784D4D-28C4-4A6D-B316-64EE710ECACB

P921

Q35064343-D736DDF7-46E2-4301-A018-D4A91B12C91B

P932

Q35064343-D6E36797-85F4-466E-A051-D6AD2B9DC633

P356

2042018813512360

P1433

Therapeutic advances in endocrinology and metabolism

P1476

Anti-vascular endothelial growth factor therapy for diabetic macular edema

@en

P2093

David S Boyer

http://www.w3.org/2001/XMLSchema#string

J Jill Hopkins

http://www.w3.org/2001/XMLSchema#string

Jason S Ehrlich

http://www.w3.org/2001/XMLSchema#string

Jonathan Sorof

http://www.w3.org/2001/XMLSchema#string

P2860

Economic costs of diabetes in the U.S. in 2012

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

Standards of medical care in diabetes--2012

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

The biology of VEGF and its receptors

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Screening for and managing diabetic retinopathy: current approaches

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology.

P304

151-169

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2042018813512360

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24324855

http://www.w3.org/2001/XMLSchema#string

P921

P932

3855829

http://www.w3.org/2001/XMLSchema#string